CM5521 Atopic Dermatitis Treatment
CMAX Clinical Research
Atopic Dermatitis (otherwise known as atopic eczema) affects both children & adults, and can cause lifelong issues for patients.
The Fusion team is working with CMAX to conduct a Phase I Trial testing a topical gel in patients with mild to moderate Atopic Dermatitis (AD). This study will take place at CMAX in the CBD.
Call 1800 150 433 today to learn more and discuss your eligibility!
Eligibility requirements
- Age: 18+
- Sex: Males & Females
- BMI: ≥40 kg
- Weight: ≥40 kg
- Medication: Have not received other recent treatment for AD No vaccines within 30 days
- Medical History: Mild to moderate Atopic Dermatitis ≥ 3 months No other dermatological conditions
Overnight Stays
- No Overnight Stays
Outpatient Visits
- 8 Visits over 3 weeks, Telehealth Appointments for Home Dosing
Payment/Remuneration
- $3,020
How to apply
Applications for this study are now closed. Please visit our list of current trials available.